Microbix Biosystems Inc. (MBX) - Total Assets

Latest as of September 2025: CA$37.41 Million CAD ≈ $27.06 Million USD

Based on the latest financial reports, Microbix Biosystems Inc. (MBX) holds total assets worth CA$37.41 Million CAD (≈ $27.06 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MBX book value for net asset value and shareholders' equity analysis.

Microbix Biosystems Inc. - Total Assets Trend (1997–2025)

This chart illustrates how Microbix Biosystems Inc.'s total assets have evolved over time, based on quarterly financial data.

Microbix Biosystems Inc. - Asset Composition Analysis

Current Asset Composition (September 2025)

Microbix Biosystems Inc.'s total assets of CA$37.41 Million consist of 63.0% current assets and 37.0% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 32.4%
Accounts Receivable CA$1.61 Million 4.3%
Inventory CA$9.20 Million 24.6%
Property, Plant & Equipment CA$10.10 Million 27.0%
Intangible Assets CA$3.73 Million 10.0%
Goodwill CA$0.00 0.0%

Asset Composition Trend (1997–2025)

This chart illustrates how Microbix Biosystems Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Microbix Biosystems Inc. market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Microbix Biosystems Inc.'s current assets represent 63.0% of total assets in 2025, a decrease from 87.9% in 1997.
  • Cash Position: Cash and equivalents constituted 32.4% of total assets in 2025, down from 67.0% in 1997.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 1997.
  • Asset Diversification: The largest asset category is property, plant & equipment at 27.0% of total assets.

Microbix Biosystems Inc. Competitors by Total Assets

Key competitors of Microbix Biosystems Inc. based on total assets are shown below.

Company Country Total Assets
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $7.59 Billion
Summit Therapeutics PLC
NASDAQ:SMMT
USA $261.73 Million
Argen-X
F:1AE
Germany €7.18 Billion
Metsera, Inc. Common Stock
NASDAQ:MTSR
USA $639.66 Million
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
China CN¥3.06 Billion
R&G PharmaStudies Co. Ltd. A
SHE:301333
China CN¥2.31 Billion
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
China CN¥819.45 Million
Innovita Biological Technology Co. Ltd. A
SHG:688253
China CN¥2.16 Billion

Microbix Biosystems Inc. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 8.48 7.15 1.62
Quick Ratio 5.17 5.24 0.59
Cash Ratio 0.00 0.00 0.00
Working Capital CA$20.80 Million CA$20.87 Million CA$2.74 Million

Microbix Biosystems Inc. - Advanced Valuation Insights

This section examines the relationship between Microbix Biosystems Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.12
Latest Market Cap to Assets Ratio 0.68
Asset Growth Rate (YoY) -1.8%
Total Assets CA$37.41 Million
Market Capitalization $25.60 Million USD

Valuation Analysis

Below Book Valuation: The market values Microbix Biosystems Inc.'s assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Microbix Biosystems Inc.'s assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Microbix Biosystems Inc. (1997–2025)

The table below shows the annual total assets of Microbix Biosystems Inc. from 1997 to 2025.

Year Total Assets Change
2025-09-30 CA$37.41 Million
≈ $27.06 Million
-1.80%
2024-09-30 CA$38.10 Million
≈ $27.56 Million
+6.85%
2023-09-30 CA$35.65 Million
≈ $25.79 Million
+7.57%
2022-09-30 CA$33.15 Million
≈ $23.98 Million
+14.97%
2021-09-30 CA$28.83 Million
≈ $20.85 Million
+84.83%
2020-09-30 CA$15.60 Million
≈ $11.28 Million
-20.54%
2019-09-30 CA$19.63 Million
≈ $14.20 Million
+1.65%
2018-09-30 CA$19.31 Million
≈ $13.97 Million
-26.96%
2017-09-30 CA$26.44 Million
≈ $19.12 Million
+4.71%
2016-09-30 CA$25.25 Million
≈ $18.26 Million
+7.22%
2015-09-30 CA$23.55 Million
≈ $17.03 Million
+30.82%
2014-09-30 CA$18.00 Million
≈ $13.02 Million
+41.55%
2013-09-30 CA$12.72 Million
≈ $9.20 Million
-5.87%
2012-09-30 CA$13.51 Million
≈ $9.77 Million
-2.19%
2011-09-30 CA$13.81 Million
≈ $9.99 Million
-3.50%
2010-09-30 CA$14.31 Million
≈ $10.35 Million
+1.58%
2009-09-30 CA$14.09 Million
≈ $10.19 Million
-3.53%
2008-09-30 CA$14.60 Million
≈ $10.56 Million
+151.70%
2007-09-30 CA$5.80 Million
≈ $4.20 Million
+46.61%
2006-09-30 CA$3.96 Million
≈ $2.86 Million
+0.19%
2005-09-30 CA$3.95 Million
≈ $2.86 Million
+17.04%
2004-09-30 CA$3.37 Million
≈ $2.44 Million
+13.32%
2003-09-30 CA$2.98 Million
≈ $2.15 Million
+9.43%
2002-09-30 CA$2.72 Million
≈ $1.97 Million
-8.00%
2001-09-30 CA$2.96 Million
≈ $2.14 Million
+1.77%
2000-09-30 CA$2.91 Million
≈ $2.10 Million
+7.64%
1999-09-30 CA$2.70 Million
≈ $1.95 Million
-67.86%
1998-09-30 CA$8.40 Million
≈ $6.08 Million
-7.69%
1997-09-30 CA$9.10 Million
≈ $6.58 Million
--

About Microbix Biosystems Inc.

TO:MBX Canada Biotechnology
Market Cap
$25.60 Million
CA$35.40 Million CAD
Market Cap Rank
#24242 Global
#920 in Canada
Share Price
CA$0.26
Change (1 day)
+0.00%
52-Week Range
CA$0.21 - CA$0.40
All Time High
CA$0.84
About

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays… Read more